HIV Infections

• 

  Subject Areas on Research

  • "Because he has bought for her, he wants to sleep with her": alcohol as a currency for sexual exchange in South African drinking venues. 
  • "Being faithful" in a sexual relationship: perceptions of Tanzanian adolescents in the context of HIV and pregnancy prevention. 
  • "Distorted into clarity": a methodological case study illustrating the paradox of systematic review. 
  • "Notify your partners--it's the law": HIV providers and mandatory disclosure. 
  • "Notify your partners--it's the law": HIV providers and mandatory disclosure. 
  • 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. 
  • 13. HIV-1 infection. 
  • 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. 
  • 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. 
  • A Bayesian method for the synthesis of evidence from qualitative and quantitative reports: the example of antiretroviral medication adherence. 
  • A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. 
  • A Pilot Trial Examining African American and White Responses to Algorithm-Guided Smoking Cessation Medication Selection in Persons Living with HIV. 
  • A Quality Improvement Project to Increase Early Detection of Syphilis Infection or Re-infection in HIV-infected Men Who Have Sex With Men. 
  • A Review of Recent Literature on Trauma Among Individuals Living with HIV. 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A brief mental health and substance abuse screener for persons with HIV. 
  • A church-based intervention for families to promote mental health and prevent HIV among adolescents in rural Kenya: Results of a randomized trial. 
  • A clinical decision support system for integrating tuberculosis and HIV care in Kenya: a human-centered design approach. 
  • A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. 
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. 
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. 
  • A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. 
  • A comparison of the adoption of electronic health records in North Carolina and South Carolina HIV systems. 
  • A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. 
  • A comparison of two visual inspection methods for cervical cancer screening among HIV-infected women in Kenya. 
  • A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. 
  • A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. 
  • A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design. 
  • A cross-site, comparative effectiveness study of an integrated HIV and substance use treatment program. 
  • A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. 
  • A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. 
  • A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. 
  • A fuzzy discrete event system approach to determining optimal HIV/AIDS treatment regimens. 
  • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. 
  • A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. 
  • A marginalized zero-inflated Poisson regression model with overall exposure effects. 
  • A mixed-methods approach to synthesizing evidence on mediators of intervention effects. 
  • A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. 
  • A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. 
  • A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines. 
  • A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. 
  • A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. 
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. 
  • A phase I/II study of the protease inhibitor indinavir in children with HIV infection. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. 
  • A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection. 
  • A plea for justice for jailed medical workers. 
  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. 
  • A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. 
  • A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. 
  • A qualitative analysis of partner selection, HIV serostatus disclosure, and sexual behaviors among HIV-positive urban men. 
  • A randomized clinical trial of a coping improvement group intervention for HIV-infected older adults. 
  • A randomized clinical trial of an intervention to promote resilience in young children of HIV-positive mothers in South Africa. 
  • A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. 
  • A randomized controlled trial of a coping group intervention for adults with HIV who are AIDS bereaved: longitudinal effects on grief. 
  • A randomized controlled trial of health information exchange between human immunodeficiency virus institutions. 
  • A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania. 
  • A randomized controlled trial of the efficacy of a stigma reduction intervention for HIV-infected women in the Deep South. 
  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 
  • A randomized trial comparing the diagnostic accuracy of visual inspection with acetic acid to Visual Inspection with Lugol's Iodine for cervical cancer screening in HIV-infected women. 
  • A randomized trial of computer-based reminders and audit and feedback to improve HIV screening in a primary care setting. 
  • A relationship-based framework of spirituality for individuals with HIV. 
  • A risk score to identify HIV-infected women most likely to become lost to follow-up in the postpartum period. 
  • A short-term group treatment model for gay male survivors of childhood sexual abuse living with HIV/AIDS. 
  • A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. 
  • A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. 
  • A single gp120 residue can affect HIV-1 tropism in macaques. 
  • A soluble inhibitor of T lymphocyte function induced by HIV-1 infection of CD4+ T cells: characterization of a cellular protein and its relationship to p15E. 
  • A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. 
  • A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. 
  • A tailored minimal self-help intervention to promote condom use in young women: results from a randomized trial. 
  • A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. 
  • A whole-genome association study of major determinants for host control of HIV-1. 
  • AIDS and HIV infection. 
  • AIDS-related grief and coping with loss among HIV-positive men and women. 
  • AIDS-related stigma, HIV testing, and transmission risk among patrons of informal drinking places in Cape Town, South Africa. 
  • Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. 
  • Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. 
  • Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. 
  • Acceptability and Accuracy of Cervical Cancer Screening Using a Self-Collected Tampon for HPV Messenger-RNA Testing among HIV-Infected Women in South Africa. 
  • Acceptability of a group intervention for initiates of antiretroviral therapy in Tanzania. 
  • Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. 
  • Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. 
  • Accuracy of visual inspection with acetic acid to detect cervical cancer precursors among HIV-infected women in Kenya. 
  • Accurate Dosing of Antiretrovirals at Home Using a Foilized, Polyethylene Pouch to Prevent the Transmission of HIV From Mother to Child. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania. 
  • Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. 
  • Acute HIV-1 Infection. 
  • Acute HIV-1 infection in the Southeastern United States: a cohort study. 
  • Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. 
  • Acyclovir in human immunodeficiency virus patients. 
  • Adaptations across clinical sites of an integrated treatment model for persons with HIV and substance abuse. 
  • Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. 
  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. 
  • Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. 
  • Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. 
  • Adherence to HAART among patients with HIV: breakthroughs and barriers. 
  • Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models. 
  • Adherence to antiretroviral therapy among HIV-infected children receiving care at Kilimanjaro Christian Medical Centre (KCMC), Northern Tanzania: A cross- sectional analytical study. 
  • Advances and failures in preventing perinatal human immunodeficiency virus infection. 
  • Affecting the planning and implementation of developmental services for children and adults with HIV infection. 
  • Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. 
  • African American grandparents' and adolescent grandchildren's sexuality communication. 
  • Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. 
  • Aging of the Liver: What This Means for Patients with HIV. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • Allocating HIV-prevention resources: balancing efficiency and equity. 
  • Alphavirus replicon particles as candidate HIV vaccines. 
  • Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. 
  • Alterations of the B-cell response by HIV-1 replication. 
  • Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. 
  • Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. 
  • An HIV self-care symptom management intervention for African American mothers. 
  • An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. 
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials. 
  • An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 
  • An empirical investigation of the relationship between spirituality, coping, and emotional distress in people living with HIV infection and AIDS. 
  • An evidence-based group coping intervention for women living with HIV and history of childhood sexual abuse. 
  • An experiment on simplifying conjoint analysis designs for measuring preferences. 
  • An integrated, multidimensional treatment model for individuals living with HIV, mental illness, and substance abuse. 
  • An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. 
  • An intracardiac mass in a young man with congenitally acquired HIV. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Anal cancer: an overview. 
  • Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. 
  • Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. 
  • Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. 
  • Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. 
  • Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins. 
  • Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. 
  • Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates. 
  • Anatomical loci of HIV-associated immune activation and association with viraemia. 
  • Ancestral and consensus envelope immunogens for HIV-1 subtype C. 
  • Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: an assessment of the feasibility of post-2015 goals. 
  • Anti-HIV-1 ADCC: clinical and therapeutic implications. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibodies for prevention of mother-to-child transmission of HIV-1. 
  • Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. 
  • Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. 
  • Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. 
  • Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. 
  • Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. 
  • Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. 
  • Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. 
  • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. 
  • Antiretroviral drug resistance among treatment-naïve HIV-1-infected persons in Washington, D.C. 
  • Antiretroviral preexposure prophylaxis for HIV prevention. 
  • Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells. 
  • Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. 
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. 
  • Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. 
  • Antiretroviral therapy: evaluating the new era in HIV treatment. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antiretroviral treatment literacy among HIV voluntary counseling and testing clients in Moshi, Tanzania, 2003 to 2005. 
  • Antiretroviral treatment strategies in resource-limited settings. 
  • Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. 
  • Antiviral therapy for human immunodeficiency virus infection in children. 
  • Anxiety and Depressive Symptoms Among People Living with HIV and Childhood Sexual Abuse: The Role of Shame and Posttraumatic Growth. 
  • Apolipoprotein E and neuromuscular disease: a critical review of the literature. 
  • Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. 
  • Aptamers: an emerging class of therapeutics. 
  • Are there adverse consequences of quizzing during informed consent for HIV research? 
  • Assay validation for left-censored data. 
  • Assessing persons with human immunodeficiency virus (HIV) infection using the Beck Depression Inventory: disease processes and other potential confounds. 
  • Assessing the effect of Measurement-Based Care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study. 
  • Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. 
  • Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation. 
  • Assessment of factors impacting cervical cancer screening among low-income women living with HIV-AIDS. 
  • Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV. 
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy. 
  • Association of knowledge on ART line of treatment, scarcity of treatment options and adherence. 
  • Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. 
  • Association of unmet needs for support services with medication use and adherence among HIV-infected individuals in the southeastern United States. 
  • Associations Between Fathers' and Sons' Sexual Risk in Rural Kenya: The Potential for Intergenerational Transmission. 
  • Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. 
  • Authors' reply: Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study: population and statistical queries. 
  • Autoantibodies to the alpha/beta T-cell receptors in human immunodeficiency virus infection: dysregulation and mimicry. 
  • Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. 
  • B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. 
  • Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. 
  • Balancing disclosure of diagnosis and assent for research in children with HIV. 
  • Barber-led sexual health education intervention for Black male adolescents and their fathers. 
  • Barriers to HIV Medication Adherence: Examining Distinct Anxiety and Depression Symptoms among Women Living with HIV Who Experienced Childhood Sexual Abuse. 
  • Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. 
  • Barriers to universal prenatal HIV testing in 4 US locations in 1997. 
  • Barriers to using text message appointment reminders in an HIV clinic. 
  • Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Battering and HIV in men who have sex with men: a critique and synthesis of the literature. 
  • Behavior and psychological functioning of young children of HIV-positive mothers in South Africa. 
  • Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. 
  • Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. 
  • Beyond Viral Neutralization. 
  • Biophysical analysis of prototype microbicidal gels. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. 
  • Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. 
  • Bispecific Antibodies Against HIV. 
  • Bivariate random effect model using skew-normal distribution with application to HIV-RNA. 
  • Black sexuality, social construction, and research targeting 'The Down Low' ('The DL'). 
  • Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity. 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021. 
  • Brief report: assessing adherence to pediatric antiretroviral regimens using the 24-hour recall interview. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • Broadly Neutralizing Antibodies and the Development of Vaccines. 
  • Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. 
  • Building a Successful Military-to-Military Partnership through Confronting HIV: The U.S-Nigeria Experience. 
  • Building capacity for cervical cancer screening in outpatient HIV clinics in the Nyanza province of western Kenya. 
  • CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. 
  • CCL3L1 and HIV/AIDS susceptibility. 
  • CCR5del32 in perinatal HIV-1 infection. 
  • CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study. 
  • CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. 
  • CD4 immunophenotyping in HIV infection. 
  • CD4 mimetics sensitize HIV-1-infected cells to ADCC. 
  • CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. 
  • CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. 
  • CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. 
  • CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. 
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. 
  • CD8(+)T-cell-mediated control of HIV-1 and SIV infection. 
  • CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. 
  • CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. 
  • CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. 
  • CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. 
  • COMPASS identifies T-cell subsets correlated with clinical outcomes. 
  • CTL cross reactivity between HIV strains. 
  • CXCL13 is a plasma biomarker of germinal center activity. 
  • Cancer Incidence following Expansion of HIV Treatment in Botswana. 
  • Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. 
  • Cancer care disparities in people with HIV in the United States. 
  • Cancer treatment disparities in HIV-infected individuals in the United States. 
  • Capacity of health-care facilities to deliver HIV treatment and care services, Northern Tanzania, 2004. 
  • Capturing the Social Location of African American Mothers Living With HIV: An Inquiry Into How Social Determinants of Health Are Framed. 
  • Cardiac Disease Associated with Human Immunodeficiency Virus Infection. 
  • Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. 
  • Cardiovascular Complications of HIV in Endemic Countries. 
  • Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications. 
  • Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya. 
  • Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. 
  • Cervical Cancer Screening Knowledge and Behavior among Women Attending an Urban HIV Clinic in Western Kenya. 
  • Cervical Cancer Stigma in Rural Kenya: What Does HIV Have to Do with It? 
  • Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count. 
  • Cervical intraepithelial neoplasia in HIV-infected women in a southeastern US population. 
  • Change point testing in logistic regression models with interaction term. 
  • Changes in HIV Outcomes Following Depression Care in a Resource-Limited Setting: Results from a Pilot Study in Bamenda, Cameroon. 
  • Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. 
  • Changes in sexual behavior of HIV-infected older adults enrolled in a clinical trial of standalone group psychotherapies targeting depression. 
  • Changes in thymic function with age and during the treatment of HIV infection. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. 
  • Characteristics of HIV voluntary counseling and testing clients before and during care and treatment scale-up in Moshi, Tanzania. 
  • Characteristics of HIV-infected adults in the Deep South and their utilization of mental health services: A rural vs. urban comparison. 
  • Characteristics of high-risk HIV-positive IDUs in Vietnam: implications for future interventions. 
  • Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 healthcare cost and utilization project. 
  • Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. 
  • Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. 
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. 
  • Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses. 
  • Characterization of primary isolate-like variants of simian-human immunodeficiency virus. 
  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. 
  • Chemokine receptors and human immunodeficiency virus infection. 
  • Chest Radiographic Findings and Outcomes of Pneumonia Among Children in Botswana. 
  • Chest radiography for predicting the cause of febrile illness among inpatients in Moshi, Tanzania. 
  • Childhood abuse and initial presentation for HIV care: an opportunity for early intervention. 
  • Childhood immunizations. 
  • Childhood sexual abuse in men who have sex with men: the current state of the science. 
  • Childhood trauma and health outcomes in HIV-infected patients: an exploration of causal pathways. 
  • Chronic kidney disease in HIV infection: an urban epidemic. 
  • Chronicity and remission of fatigue in patients with established HIV infection. 
  • Cigarette smoking and drug use among a nationally representative sample of HIV-positive individuals. 
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. 
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. 
  • Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. 
  • Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV. 
  • Clinical and radiographic predictors of the etiology of pulmonary nodules in HIV-infected patients. 
  • Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). 
  • Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. 
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. 
  • Clonal and spontaneous origins of fluconazole resistance in Candida albicans. 
  • Co-occurring psychosocial problems and HIV risk among women attending drinking venues in a South African township: a syndemic approach. 
  • Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. 
  • Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. 
  • Cocaine dependence modulates the effect of HIV infection on brain activation during intertemporal decision making. 
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. 
  • Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region beta repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus-infected children. 
  • Combination antiretroviral therapy. 
  • Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. 
  • Commentary: cardiovascular risk factors--the next epidemic in Uganda: findings from the population-based HIV/AIDS rural surveillance cohort. 
  • Common genetic variation and the control of HIV-1 in humans. 
  • Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. 
  • Community-level HIV prevention for persons with severe mental illness living in supportive housing programs: a pilot intervention study. 
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. 
  • Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. 
  • Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. 
  • Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. 
  • Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. 
  • Comparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Compensatory activation in fronto-parietal cortices among HIV-infected persons during a monetary decision-making task. 
  • Complement and the control of HIV infection: an evolving story. 
  • Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). 
  • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
  • Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. 
  • Complex immune correlates of protection in HIV-1 vaccine efficacy trials. 
  • Complications and Route of Delivery in a Large Cohort Study of HIV-1-Infected Women-IMPAACT P1025. 
  • Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China. 
  • Concentrations of protease inhibitors in cord blood after in utero exposure. 
  • Concerted use of immunologic and ultrastructural analyses in diagnostic medicine: immunoelectron microscopy and correlative microscopy. 
  • Concordance between self-reported substance use and toxicology among HIV-infected and uninfected at risk youth. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. 
  • Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. 
  • Contraceptive service delivery in Kenya: A qualitative study to identify barriers and preferences among female sex workers and health care providers. 
  • Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Coping strategies and emotional wellbeing among HIV-infected men and women experiencing AIDS-related bereavement. 
  • Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. 
  • Coping styles and illicit drug use in older adults with HIV/AIDS. 
  • Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. 
  • Correlates of HIV testing among abused women in South Africa. 
  • Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. 
  • Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. 
  • Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. 
  • Cost effectiveness of treating asymptomatic HIV infection. 
  • Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments. 
  • Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. 
  • Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. 
  • Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. 
  • Cost-effectiveness of voluntary HIV screening in Russia. 
  • Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered? 
  • Crescentic IgA nephropathy and acute renal failure in an HIV-positive patient with enteric salmonella infection. 
  • Criterion-related validity of a diarrhea questionnaire in HIV-infected patients. 
  • Critical issues in mucosal immunity for HIV-1 vaccine development. 
  • Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. 
  • Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. 
  • Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. 
  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 
  • Current and future treatment of HIV infection. 
  • Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics. 
  • Current issues in global tuberculosis control. 
  • Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. 
  • Cutaneous manifestations of HIV infection in children. 
  • Cutaneous manifestations of pediatric HIV infection. 
  • Cutpoint selection for categorizing a continuous predictor. 
  • Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. 
  • DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. 
  • Daytime sleepiness, nighttime sleep quality, stressful life events, and HIV-related fatigue. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Defensins: natural anti-HIV peptides. 
  • Defining the rural HIV epidemic: correlations of 3 definitions--South Carolina, 2005-2011. 
  • Definition of proteinuria among women with HIV infection. 
  • Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. 
  • Delayed-type hypersensitivity testing in Tanzanian adults with HIV infection. 
  • Demographic and illness-related variables associated with HIV-related fatigue. 
  • Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. 
  • Depression and Engagement in Care Among Newly Diagnosed HIV-Infected Adults in Johannesburg, South Africa. 
  • Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. 
  • Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. 
  • Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. 
  • Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. 
  • Designing synthetic vaccines for HIV. 
  • Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. 
  • Detection of HIV-2 by PCR. 
  • Detection of bloodstream pathogens in a bacille Calmette-Guérin (BCG)-vaccinated pediatric population in Malawi: a pilot study. 
  • Detection of minor drug-resistant populations by parallel allele-specific sequencing. 
  • Determinants of Intimate Partner Violence Among HIV-Positive and HIV-Negative Women in India. 
  • Determinants of increased energy expenditure in HIV-infected women. 
  • Developing a family-based HIV prevention intervention in rural Kenya: challenges in conducting community-based participatory research. 
  • Developing a matrix to identify and prioritise research recommendations in HIV prevention. 
  • Developing an HIV vaccine. 
  • Development and evaluation of an HIV-risk reduction program for female college students. 
  • Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. 
  • Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. 
  • Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. 
  • Development of fatal acute liver failure in HIV-HBV coinfected patients. 
  • Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. 
  • Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. 
  • Developmental pharmacokinetic changes of Lamivudine in infants and children. 
  • Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity. 
  • Diagnosing HIV infection in primary care settings: missed opportunities. 
  • Diagnosing Rhodococcus equi infections in a setting where tuberculosis is highly endemic: a double challenge. 
  • Diagnosis and screening of HIV/AIDS using clinical criteria in Tanzanian adults. 
  • Diagnosis of acute HIV infection in Connecticut. 
  • Differences between completers and early dropouts from 2 HIV intervention trials: a health belief approach to understanding prevention program attrition. 
  • Differences in HIV risk characteristics between bisexual and exclusively gay men. 
  • Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. 
  • Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. 
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. 
  • Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. 
  • Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapy. 
  • Disorders of the nails and hair associated with human immunodeficiency virus infection. 
  • Disparities in Depressive Symptoms and Antidepressant Treatment by Gender and Race/Ethnicity among People Living with HIV in the United States. 
  • Disparities in cancer treatment among patients infected with the human immunodeficiency virus. 
  • Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. 
  • Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. 
  • Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. 
  • Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. 
  • Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection. 
  • Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains. 
  • Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. 
  • Diversity considerations in HIV-1 vaccine selection. 
  • Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. 
  • Do United States-based Medicaid spend-down programmes make public sense for persons with HIV/AIDS? 
  • Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial. 
  • Does RNA interference have a future as a treatment for HIV-1 induced disease? 
  • Does this adult patient have early HIV infection?: The Rational Clinical Examination systematic review. 
  • Domestic violence among adolescents in HIV prevention research in Tanzania: participant experiences and measurement issues. 
  • Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. 
  • Don't share razors or toothbrushes. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: the importance of an event-level focus for promoting safer sexual behaviors. 
  • Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. 
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. 
  • Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. 
  • Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. 
  • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. 
  • Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. 
  • Dynamics of syncytium-inducing and non-syncytium-inducing type 1 human immunodeficiency viruses during primary infection. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Early detection: the next steps. 
  • Early language development in children exposed to or infected with human immunodeficiency virus. 
  • Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Early zidovudine and survival in HIV infection. 
  • Early zidovudine and survival in HIV infection. The Veterans Affairs AIDS Cooperative Studies Group. 
  • Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. 
  • Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. 
  • Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. 
  • Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. 
  • Effect of human immunodeficiency virus infection on serum beta2-microglobulin levels in pregnant women. 
  • Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. 
  • Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. 
  • Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. 
  • Effect of pregnancy and human immunodeficiency virus infection on intracellular interleukin-2 production patterns. 
  • Effect of smoking on the clinical progression of HIV-1 infection. 
  • Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. 
  • Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania. 
  • Effectiveness of HIV prevention interventions in developing countries. 
  • Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. 
  • Effects of HIV infection on the metabolic and hormonal status of children with severe acute malnutrition. 
  • Effects of a coping intervention on transmission risk behavior among people living with HIV/AIDS and a history of childhood sexual abuse. 
  • Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. 
  • Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. 
  • Effects of human immunodeficiency virus type 1 on CD4 lymphocyte subset activation. 
  • Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients. 
  • Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys. 
  • Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. 
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. 
  • Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. 
  • Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. 
  • Eighth Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, California, June 3-5, 2010. 
  • Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. 
  • Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. 
  • Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. 
  • Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. 
  • Emotional adjustment in survivors of sexual assault living with HIV-AIDS. 
  • Emotional distress in African American women with HIV. 
  • Ending HIV-related stigma: nursing's opportunity to lead. 
  • Endogenous opioids and HIV infection. 
  • Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. 
  • Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay. 
  • Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Enhanced p24 antigen detection in sera from human immunodeficiency virus-infected children. 
  • Enhancing linkage and retention in HIV care: a review of interventions for highly resourced and resource-poor settings. 
  • Enhancing physical function in HIV-infected older adults: A randomized controlled clinical trial. 
  • Entry-Level Competencies Required of Primary Care Nurse Practitioners Providing HIV Specialty Care: A National Practice Validation Study. 
  • Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). 
  • Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains. 
  • Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. 
  • Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. 
  • Epidemiology of human immunodeficiency virus testing among patients with tuberculosis in North Carolina. 
  • Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication. 
  • Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. 
  • Essential core competencies related to HIV and AIDS are critically needed in nursing. 
  • Essential nursing competencies related to HIV and AIDS. 
  • Essential nursing competencies related to HIV and AIDS: Executive summary. 
  • Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. 
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. 
  • Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. 
  • Ethical beliefs related to HIV and AIDS among nursing students in South Africa and the United States: a cross-sectional analysis. 
  • Ethical dilemma in continuing a zidovudine-placebo trial in symptomatic human immunodeficiency virus infection. 
  • Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. 
  • Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. 
  • Evaluating mental health difficulties and associated outcomes among HIV-positive adolescents in Tanzania. 
  • Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. 
  • Evaluation and management of fungal infections in immunocompromised patients. 
  • Evaluation of T-lymphocyte subsets present in semen and peripheral blood of healthy donors: a report from the heterosexual transmission study. 
  • Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. 
  • Evaluation of denoising algorithms for biological electron tomography. 
  • Evaluation of longitudinal clinical outcomes and adherence to care among HIV-infected refugees. 
  • Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. 
  • Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. 
  • Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds. 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. 
  • Evidence for susceptibility of intrathymic T cell precursors to human immunodeficiency virus infection: a mechanism for T4 (CD4) lymphocyte depletion. 
  • Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. 
  • Evidence that Par-4 participates in the pathogenesis of HIV encephalitis. 
  • Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. 
  • Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. 
  • Evidence-Based Strategies for Shortening Informed Consent Forms in Clinical Research. 
  • Evidence-based clinical practice guidelines for managing depression in persons living with HIV. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. 
  • Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. 
  • Exercise and the treatment of wasting: aging and human immunodeficiency virus infection. 
  • Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. 
  • Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • Explaining long-term HIV survivors. 
  • Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. 
  • Exploring the HIV continuum of care among young black MSM. 
  • Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. 
  • Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993 - 2006. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • Facing the challenge of HIV. Primary care physicians have an obligation to care for those infected. 
  • Factors associated with change in sexual transmission risk behavior over 3 years among HIV-infected patients in Tanzania. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. 
  • Factors associated with recurrence of cervical intraepithelial neoplasia 2+ after treatment among HIV-infected women in Western Kenya. 
  • Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. 
  • Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. 
  • Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. 
  • Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. 
  • Fast Dissemination of New HIV-1 CRF02/A1 Recombinants in Pakistan. 
  • Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. 
  • Fatigue in HIV-Infected People: A Three-Year Observational Study. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. 
  • Feasibility of integrated depression care in an HIV clinic. 
  • Feasibility of nurse-led antidepressant medication management of depression in an HIV clinic in Tanzania. 
  • Feasibility of using an iPod touch device and acceptability of a stigma reduction intervention with HIV-infected women in the Deep South. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Fever and Rash in a Patient With Hepatitis. 
  • Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients >/=15 years old, Bangkok. 
  • Filgrastim in patients with neutropenia: potential effects on quality of life. 
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. 
  • Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. 
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Focusing HIV prevention on those most likely to transmit the virus. 
  • Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. 
  • Food Insecurity Is Associated with Cognitive Deficits Among HIV-Positive, But Not HIV-Negative, Individuals in a United States Sample. 
  • Frequency of atazanavir-associated leukocyturia development and renal function decline. 
  • From the Institute of Medicine. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • Fungal infections in HIV/AIDS. 
  • GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality. 
  • Gastric graft-versus-host disease: a blinded histologic study. 
  • Gay identity, interpersonal violence, and HIV risk behaviors: an empirical test of theoretical relationships among a probability-based sample of urban men who have sex with men. 
  • Gender differences in knowledge and perceptions of HIV resources among individuals living with HIV in the Southeast. 
  • Gender differences in the rates and correlates of HIV risk behaviors among drug abusers. 
  • Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. 
  • Gender moderates the influence of psychosocial factors and drug use on HAART adherence in the context of HIV and childhood sexual abuse. 
  • Gender-based violence and HIV sexual risk behavior: alcohol use and mental health problems as mediators among women in drinking venues, Cape Town. 
  • Gender-based violence, alcohol use, and sexual risk among female patrons of drinking venues in Cape Town, South Africa. 
  • Gene Editing: A New Tool for Viral Disease. 
  • Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. 
  • Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. 
  • Generic and branded drugs for the treatment of people living with HIV/AIDS. 
  • Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. 
  • Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. 
  • Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. 
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 
  • Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. 
  • Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. 
  • Genetic risk factors for perinatally acquired HIV-1 infection. 
  • Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. 
  • Genetically and epidemiologically related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. 
  • Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. 
  • Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study. 
  • Global dimensions of the AIDS epidemic: implications for prevention and care. 
  • Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. 
  • Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. 
  • Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β. 
  • Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity. 
  • Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. 
  • Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. 
  • Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. 
  • Gut microbes out of control in HIV infection. 
  • HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study. 
  • HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. 
  • HIV Diagnoses, Prevalence and Outcomes in Nine Southern States. 
  • HIV Infection and AIDS in the Deep South. 
  • HIV Infection and Survival Among Women With Cervical Cancer. 
  • HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. 
  • HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. 
  • HIV Risk Behavior Among Methamphetamine Users Entering Substance Abuse Treatment in Cape Town, South Africa. 
  • HIV and AIDS: issues for women in Australia. 
  • HIV and cardiovascular disease in sub-Saharan Africa: the Sutton Law as applied to global health. 
  • HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. 
  • HIV and older adults: clinical outcomes in the era of HAART. 
  • HIV and pregnancy: considerations for nursing practice. 
  • HIV antibodies for treatment of HIV infection. 
  • HIV antibody testing of gay men in smaller US cities. 
  • HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 
  • HIV community viral load trends in South Carolina. 
  • HIV entry inhibitors: progress in development and application. 
  • HIV envelope gp120 activates human arterial smooth muscle cells. 
  • HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. 
  • HIV fusion and its inhibition. 
  • HIV heterosexual transmission: a hypothesis about an additional potential determinant. 
  • HIV immune reconstitution syndrome in sub-Saharan Africa. 
  • HIV infection and the dynamic interplay between the thymus and the peripheral T cell pool. 
  • HIV infection in vaccinated volunteers. 
  • HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. 
  • HIV infection presenting as an unusually large pure yolk sac tumor of the testis. 
  • HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression. 
  • HIV infection-induced transcriptional program in renal tubular epithelial cells activates a CXCR2-driven CD4+ T-cell chemotactic response. 
  • HIV infection: treatment outcomes in older and younger adults. 
  • HIV medical care provider practices for reducing high-risk sexual behavior: results of a qualitative study. 
  • HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. 
  • HIV pre-exposure prophylaxis. 
  • HIV prevention and care in incarcerated populations. 
  • HIV results in the frame. Paradox remains. 
  • HIV risk behavior among adults with severe mental illness: a systematic review. 
  • HIV risk behavior among ethnically diverse adolescents living in low-income housing developments. 
  • HIV risk behavior in opioid dependent adults seeking detoxification treatment: an exploratory comparison of heroin and oxycodone users. 
  • HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. 
  • HIV risk behaviors among inner-city African American women. 
  • HIV risk behaviors among women living in low-income, inner-city housing developments. 
  • HIV serostatus disclosure in the treatment cascade: evidence from Northern Tanzania. 
  • HIV testing and sero-prevalence among methamphetamine users seeking substance abuse treatment in Cape Town. 
  • HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment. 
  • HIV testing behaviors and attitudes among community recruited methamphetamine users in a South African township. 
  • HIV testing preferences in Tanzania: a qualitative exploration of the importance of confidentiality, accessibility, and quality of service. 
  • HIV transmission in a dental practice. 
  • HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. 
  • HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. 
  • HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. 
  • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV vaccine development: perspective. 
  • HIV vaccine rationale, design and testing. 
  • HIV vaccines. Viral envelope fails to deliver? 
  • HIV vaccines: brief review and discussion of future directions. 
  • HIV vaccines: where we are and where we are going. 
  • HIV's challenge to measles control. 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. 
  • HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. 
  • HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. 
  • HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication. 
  • HIV-1 Neutralizing Antibodies: Understanding Nature's Pathways 
  • HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
  • HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. 
  • HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? 
  • HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. 
  • HIV-1 dynamics in children. 
  • HIV-1 dynamics in haemodialysis patients. 
  • HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. 
  • HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. 
  • HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. 
  • HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. 
  • HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 
  • HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. 
  • HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. 
  • HIV-1 infected women and prenatal care utilization: barriers and facilitators. 
  • HIV-1 infection in injection drug users. 
  • HIV-1 infection in the lymphoid organs. 
  • HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. 
  • HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. 
  • HIV-1 infection: fooling the gatekeeper. 
  • HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. 
  • HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. 
  • HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. 
  • HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. 
  • HIV-1 vaccines and adaptive trial designs. 
  • HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes. 
  • HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. 
  • HIV-1-specific antibody responses during acute and chronic HIV-1 infection. 
  • HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. 
  • HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. 
  • HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. 
  • HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. 
  • HIV-infected mothers' foci of concern during the viral testing of their infants. 
  • HIV-related shame and health-related quality of life among older, HIV-positive adults. 
  • HIV-related stigma among an urban sample of persons living with HIV at risk for dropping out of HIV-oriented primary medical care. 
  • HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. 
  • HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. 
  • HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. 
  • HIV. A clever hijacker of the immune system. 
  • HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. 
  • HIV/AIDS and the African-American community: a state of emergency. 
  • HIV/AIDS in the Southern USA: a disproportionate epidemic. 
  • HIV/AIDS stigma in a South African community. 
  • HIV/AIDS-related institutional mistrust among multiethnic men who have sex with men: effects on HIV testing and risk behaviors. 
  • HIV/AIDS-related stigma in South African alcohol-serving venues and its potential impact on HIV disclosure, testing and treatment-seeking behaviours. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. 
  • HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. 
  • HPTN 062: A Pilot Randomized Controlled Trial Exploring the Effect of a Motivational-Interviewing Intervention on Sexual Behavior among Individuals with Acute HIV Infection in Lilongwe, Malawi. 
  • HPTN 062: a feasibility and acceptability pilot intervention to reduce HIV transmission risk behaviors among individuals with acute and early HIV infection in Lilongwe, Malawi. 
  • HPV clearance and the neglected role of stochasticity. 
  • Has the HIV epidemic in rural Mwanza, Tanzania reached a plateau? 
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. 
  • Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. 
  • Health education: historic windows of opportunity. 
  • Health education: historic windows of opportunity. 
  • Health literacy of HIV-positive individuals enrolled in an outreach intervention: results of a cross-site analysis. 
  • HealthMpowerment.org: Building Community Through a Mobile-Optimized, Online Health Promotion Intervention. 
  • Healthcare access and utilization by patients infected with human immunodeficiency virus: does gender matter? 
  • Heart failure in sub-Saharan Africa. 
  • Hematopoietic cell transplantation with cord blood for cure of HIV infections. 
  • Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. 
  • Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. 
  • Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. 
  • Heterogeneous HIV testing preferences in an urban setting in Tanzania: results from a discrete choice experiment. 
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. 
  • Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. 
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. 
  • Heterosexual Anal Sex Among Men and Women in Substance Abuse Treatment: Secondary Analysis of Two Gender-Specific HIV-Prevention Trials. 
  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. 
  • High prevalence of PI resistance in patients failing second-line ART in Vietnam. 
  • High prevalence of malaria parasitemia and anemia among hospitalized children in Rakai, Uganda. 
  • High risk sexual behavior and alcohol consumption among bar-going gay men. 
  • High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. 
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. 
  • High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems. 
  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. 
  • Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. 
  • Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. 
  • Highly stressed: stressful and traumatic experiences among individuals with HIV/AIDS in the Deep South. 
  • Host controls of HIV broadly neutralizing antibody development. 
  • Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. 
  • How do North Carolina prenatal care providers counsel and test pregnant women for HIV? Survey measures knowledge of HIV testing benefits. 
  • How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. 
  • Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. 
  • Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. 
  • Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. 
  • Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. 
  • Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. 
  • Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. 
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. 
  • Human immunodeficiency virus and AIDS. 1993 update. 
  • Human immunodeficiency virus infection in childhood: the disease and its cutaneous manifestations. 
  • Human immunodeficiency virus transmission by child sexual abuse. 
  • Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. 
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. 
  • Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. 
  • Human immunodeficiency virus type 1 molecular evolution and the measure of selection. 
  • Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. 
  • Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. 
  • Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. 
  • Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. 
  • Hypertrophic herpes simplex virus in HIV patients. 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • IMPLEMENTATION OF A SCHOOL-BASED HIV PREVENTION CURRICULUM FOLLOWING NATIONAL DISSEMINATION IN NYANZA PROVINCE, KENYA. 
  • IRT health outcomes data analysis project: an overview and summary. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. 
  • Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. 
  • Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. 
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. 
  • Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. 
  • Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. 
  • Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. 
  • Identifying acute HIV infection in Rhode Island. 
  • Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. 
  • Idiopathic autoimmune thrombocytopenic purpura. 
  • If you build it will they come? Addressing social isolation within a technology-based HIV intervention for young black men who have sex with men. 
  • Illuminating meaning and transforming issues of spirituality in HIV disease and AIDS: an application of Parse's theory of human becoming. 
  • Image of the month. Syphilitic proctitis. 
  • Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. 
  • Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. 
  • Immune correlates of vaccine protection against HIV-1 acquisition. 
  • Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. 
  • Immune reconstitution in patients with HIV infection. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immune-based interventions to prevent postnatal HIV-1 transmission. 
  • Immune-correlates analysis of an HIV-1 vaccine efficacy trial. 
  • Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. 
  • Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. 
  • Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. 
  • Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. 
  • Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. 
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. 
  • Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. 
  • Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. 
  • Immunologic targets of HIV infection: T cells. NICHD IVIG Clinical Trial Group, and the NHLBI P2C2 Pediatric Pulmonary and Cardiac Complications of HIV Infection Study Group. 
  • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. 
  • Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. 
  • Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. 
  • Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. 
  • Impact of a routine, opt-out HIV testing program on HIV testing and case detection in North Carolina sexually transmitted disease clinics. 
  • Impact of an educational programme on reproductive health among young migrant female workers in Shenzhen, China: an intervention study. 
  • Impact of bereavement on progression of AIDS and HIV infection: a review. 
  • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. 
  • Impact of genotypic resistance testing on physician selection of antiretroviral therapy. 
  • Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study. 
  • Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. 
  • Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL). 
  • Implementation of antiretroviral therapy adherence interventions: a realist synthesis of evidence. 
  • Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. 
  • Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. 
  • Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial. 
  • Improvements in depression and changes in quality of life among HIV-infected adults. 
  • Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care. 
  • Improving care of chronic conditions for women veterans: identifying opportunities for comparative effectiveness research. 
  • Improving defences at the portal of HIV entry: mucosal and innate immunity. 
  • Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast. 
  • In or out? Methodological considerations for including and excluding findings from a meta-analysis of predictors of antiretroviral adherence in HIV-positive women. 
  • In their own voices: a qualitative study of women's risk for intimate partner violence and HIV in South Africa. 
  • In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. 
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. 
  • Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. 
  • Incident stressful and traumatic life events and human immunodeficiency virus sexual transmission risk behaviors in a longitudinal, multisite cohort study. 
  • Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. 
  • Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy. 
  • Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects. 
  • Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. 
  • Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. 
  • Independent effects of HIV infection and cocaine dependence on neurocognitive impairment in a community sample living in the southern United States. 
  • Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. 
  • Individual- and family-level psychosocial correlates of HIV risk behavior among youth in rural Kenya. 
  • Individuals motivated to participate in adherence, care and treatment (imPACT): development of a multi-component intervention to help HIV-infected recently incarcerated individuals link and adhere to HIV care. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. 
  • Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. 
  • Ineffective use of condoms among young women in managed care. 
  • Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. 
  • Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. 
  • Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. 
  • Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. 
  • Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 
  • Influence of prothymosin-alpha on HIV-1 target cells. 
  • Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. 
  • Influencing medication adherence among women with AIDS. 
  • Informing the dosing of interventions in randomized trials. 
  • Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. 
  • Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. 
  • Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. 
  • Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. 
  • Inhibition of interleukin-2 and interferon-gamma by an HIV-1 Nef-encoded synthetic peptide. 
  • Inhibition of productive human immunodeficiency virus-1 infection by cobalamins. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. 
  • Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. 
  • Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. 
  • Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Insomnia in HIV-infected patients: pathophysiologic implications. 
  • Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. 
  • Integrated screening for tuberculosis and HIV in tuberculosis contact investigations: lessons learned in North Carolina. 
  • Integrating HIV prevention into services for abused women in South Africa. 
  • Integrating family planning services into HIV care and treatment clinics in Tanzania: evaluation of a facilitated referral model. 
  • Integration of statistical theory and practical clinical expertise. Polymerase chain reaction testing of the HIV-exposed infant. 
  • Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study. 
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. 
  • Interest in quitting and lifetime quit attempts among smokers living with HIV infection. 
  • Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients. 
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. 
  • Intestinal parasites and HIV infection in Tanzanian children with chronic diarrhea. 
  • Intimate partner violence and the association with HIV risk behaviors among young men in Dar es Salaam, Tanzania. 
  • Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. 
  • Invasive disease caused by nontuberculous mycobacteria, Tanzania. 
  • Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, Malawi. 
  • Is anybody out there? Integrating HIV services in rural regions. 
  • Is developing an HIV-1 vaccine possible? 
  • Is the HCV pipeline heading in the right direction? 
  • Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy? 
  • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Isoniazid preventive therapy in medium-incidence settings: the price is right. 
  • Kaposi sarcoma presenting as yellow-green penile plaques in a black man with HIV. 
  • Kaposi's sarcoma. 
  • Kaposi's-sarcoma-associated herpesvirus is detected in peripheral blood mononuclear cells of HIV-infected homosexuals more often than in heterosexuals. 
  • Key references in infectious diseases pharmacotherapy. 
  • Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. 
  • Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. 
  • Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. 
  • Knowledge and risks of human immunodeficiency virus transmission among veterans with severe mental illness. 
  • Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. 
  • Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. 
  • Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. 
  • Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. 
  • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. 
  • Late diagnosis of HIV infection: the role of age and sex. 
  • Late treatment of HIV infection--is it better? 
  • Latency reversal and viral clearance to cure HIV-1. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Leptospirosis and human immunodeficiency virus co-infection among febrile inpatients in northern Tanzania. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. 
  • Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. 
  • Lessons learned from HIV-1 vaccine trials: new priorities and directions. 
  • Lessons learned from human HIV vaccine trials. 
  • Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. 
  • Levels and predictors of HIV risk behavior among women in low-income public housing developments. 
  • Linguistic and Cultural Adaptation of a Computer-Based Counseling Program (CARE+ Spanish) to Support HIV Treatment Adherence and Risk Reduction for People Living With HIV/AIDS: A Randomized Controlled Trial. 
  • Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA. 
  • Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. 
  • Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. 
  • Long-term correlates of childhood abuse among adults with severe mental illness: adult victimization, substance abuse, and HIV sexual risk behavior. 
  • Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. 
  • Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. 
  • Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. 
  • Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. 
  • Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection. 
  • Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. 
  • Low prevalence of Pneumocystis jirovecii lung colonization in Ugandan HIV-infected patients hospitalized with non-Pneumocystis pneumonia. 
  • Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian in-patients. 
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. 
  • Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome. 
  • Lymphocyte subsets in children younger than 2 years old: normal values in a population at risk for human immunodeficiency virus infection and diagnostic and prognostic application to infected children. 
  • Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. 
  • MHC class II alleles associated with clinical and immunological manifestations of HIV-1 infection among children in Catalonia, Spain. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Maintaining normalcy: a grounded theory of engaging in HIV-oriented primary medical care. 
  • Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. 
  • Making AIDS prevention a national priority. 
  • Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. 
  • Management of HIV in pregnancy. 
  • Management of adolescents and adults with febrile illness in resource limited areas. 
  • Management of antiretroviral therapy. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Managing depression in countries with low and middle incomes: an imperative for human immunodeficiency virus/acquired immune deficiency syndrome care and treatment and general public health. 
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 
  • Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. 
  • Marijuana use and sex with multiple partners among lesbian, gay and bisexual youth: results from a national sample. 
  • Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. 
  • Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. 
  • Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. 
  • Maternal acceptance of voluntary human immunodeficiency virus antibody testing during the newborn period with the Guthrie card. 
  • Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. 
  • Mathematical models of HIV infection. I. Threshold conditions for transmission and host survival. 
  • Mathematical models of HIV pathogenesis. 
  • Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. 
  • Measles immunity in HIV-infected children. 
  • Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease. 
  • Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale. 
  • Mechanisms by which HIV envelope minimizes immunogenicity. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. 
  • Men who report recent male and female sex partners in Cape Town, South Africa: an understudied and underserved population. 
  • Men's Behavior Predicts Women's Risks for HIV/AIDS: Multilevel Analysis of Alcohol-Serving Venues in South Africa. 
  • Men's knowledge and attitudes about cervical cancer screening in Kenya. 
  • Meningococcemia in a patient coinfected with hepatitis C virus and HIV. 
  • Mental health and HIV sexual risk behavior among patrons of alcohol serving venues in Cape Town, South Africa. 
  • Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. 
  • Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. 
  • Metasynthesis of qualitative research on living with HIV infection. 
  • Methamphetamine use is associated with childhood sexual abuse and HIV sexual risk behaviors among patrons of alcohol-serving venues in Cape Town, South Africa. 
  • Microalbuminuria predicts overt proteinuria among patients with HIV infection. 
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Mindfulness-Based Stress Reduction in Advanced Nursing Practice: A Nonpharmacologic Approach to Health Promotion, Chronic Disease Management, and Symptom Control. 
  • Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. 
  • Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South. 
  • Missed opportunities for religious organizations to support people living with HIV/AIDS: findings from Tanzania. 
  • Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 
  • Mobile phone applications for the care and prevention of HIV and other sexually transmitted diseases: a review. 
  • Mode of delivery and infant respiratory morbidity among infants born to HIV-1-infected women. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Modulation of HIV-1 immunity by adjuvants. 
  • Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. 
  • Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. 
  • Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. 
  • Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. 
  • Morbidity and mortality among a cohort of HIV-infected adults in a programme for community home-based care, in the Kilimanjaro Region of Tanzania (2003-2005). 
  • Mortality from sexually transmitted diseases in reproductive-aged women: United States, 1999-2010. 
  • Mortality in primary and secondary myocarditis. 
  • Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. 
  • Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. 
  • Mother to child HIV transmission. 
  • Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides. 
  • Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. 
  • Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. 
  • Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. 
  • Multifocal osteonecrosis and human immunodeficiency virus infection. 
  • Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa. 
  • Multiple CTL specificities against autologous HIV-1-infected BLCLs. 
  • Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. 
  • Multiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy Outcomes. 
  • Multiple partners, risky partners and HIV risk among low-income urban women. 
  • Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. 
  • Multisite comparison of methods for the quantitation of the surface expression of CD38 on CD8(+) T lymphocytes. The ACTG Advanced Flow Cytometry Focus Group. 
  • Mycobacteria in stool specimens: the nonvalue of smears for predicting culture results. 
  • Mycobacterial disease in AIDS. 
  • NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses. 
  • Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. 
  • Natural immunity to HIV and its possible relationship to vaccine strategies. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. 
  • Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. 
  • Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. 
  • Negotiating risk: knowledge and use of HIV prevention by persons with serious mental illness living in supportive housing. 
  • Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. 
  • Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. 
  • Neopterin production by HIV-1-infected mononuclear phagocytes. 
  • Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. 
  • Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. 
  • Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. 
  • Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. 
  • Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. 
  • Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. 
  • Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? 
  • Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. 
  • Neutralizing antibodies take a swipe at HIV in vivo. 
  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 
  • Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. 
  • New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. 
  • New approaches to HIV vaccine development. 
  • New frontiers of immunotherapy for HIV. 
  • New mothers' knowledge and attitudes about perinatal human immunodeficiency virus infection. 
  • Newer treatments for HIV in children. 
  • Non-cigarette tobacco and poly-tobacco use among persons living with HIV drawn from a nationally representative sample. 
  • Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. 
  • Noncytolytic CD8 T cell-mediated suppression of HIV replication. 
  • Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. 
  • Nontypeable Haemophilus influenzae meningitis complicated by hearing loss in a 9-year-old HIV-infected boy. 
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. 
  • Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. 
  • Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 
  • OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry. 
  • Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. 
  • Observational cohort study of HIV-infected African children. 
  • Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings. 
  • Occupational Risk Factors for Tuberculosis Among Healthcare Workers in KwaZulu-Natal, South Africa. 
  • Ocular parameters of biological ageing in HIV-infected individuals in South Africa: relationship with chronological age and systemic biomarkers of ageing. 
  • Okukkera Ng'omuzungu (lost in translation): understanding the social value of global health research for HIV/AIDS research participants in Uganda. 
  • Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. 
  • On being poor with HIV. 
  • One size does not fit all: HIV testing preferences differ among high-risk groups in Northern Tanzania. 
  • Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. 
  • Opening Aeolus' Bag of Winds: Acute Abdominal Pain in a Severely Immunosuppressed Patient. 
  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. 
  • Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. 
  • Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Oral SIV, SHIV, and HIV type 1 infection. 
  • Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. 
  • Organ transplantation in HIV-infected patients. 
  • Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. 
  • Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. 
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. 
  • Orphan status, HIV risk behavior, and mental health among adolescents in rural Kenya. 
  • Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women. 
  • Outcomes from a group intervention for coping with HIV/AIDS and childhood sexual abuse: reductions in traumatic stress. 
  • Outcomes from a randomized controlled trial of a group intervention for HIV positive men and women coping with AIDS-related loss and bereavement. 
  • Outcomes of a randomized community-level HIV prevention intervention for women living in 18 low-income housing developments. 
  • Outcomes of a randomized, controlled community-level HIV prevention intervention for adolescents in low-income housing developments. 
  • Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. 
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. 
  • Overview: HIV/AIDS in the deep south region of the United States. 
  • PHOTON-2: hope for patients with HIV and HCV co-infection? 
  • PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi. 
  • PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. 
  • Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States. 
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. 
  • Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. 
  • Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. 
  • Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion. 
  • Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. 
  • Participatory mapping in low-resource settings: Three novel methods used to engage Kenyan youth and other community members in community-based HIV prevention research. 
  • Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? 
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. 
  • Pathogenesis and natural history of HIV infection. 
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. 
  • Pathogenic Escherichia coli in children with and without chronic diarrhea in Tanzania. 
  • Patient and provider perspectives on implementation models of HIV counseling and testing for patients with TB. 
  • Patient attitudes toward rooming with persons with HIV infection. 
  • Patterns and correlates of sexual activity and condom use behavior in persons 50-plus years of age living with HIV/AIDS. 
  • Patterns of HIV disclosure and condom use among HIV-infected young racial/ethnic minority men who have sex with men. 
  • Pediatric HIV infection in Elista, Russia: interventional strategies. 
  • Pediatric HIV infection. An update. 
  • People living with HIV infection who attend and do not attend support groups: a pilot study of needs, characteristics and experiences. 
  • Perceived acceptability of home-based couples voluntary HIV counseling and testing in Northern Tanzania. 
  • Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. 
  • Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. 
  • Perceptions of the role of maternal nutrition in HIV-positive breast-feeding women in Malawi. 
  • Perceptions of voluntary medical male circumcision among circumcising and non-circumcising communities in Malawi. 
  • Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. 
  • Perinatal depression in HIV-infected African women: a systematic review. 
  • Perioperative management of special populations: immunocompromised host (cancer, HIV, transplantation). 
  • Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus. 
  • Perspectives on the development of anti-HIV vaccines. 
  • Pervasive genomic recombination of HIV-1 in vivo. 
  • Pharmacogenetics to predict drug-related adverse events. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. 
  • Pharmacokinetics and tolerance of zidovudine in preterm infants. 
  • Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. 
  • Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. 
  • Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study. 
  • Pharmacological considerations in human immunodeficiency virus-infected adults in the intensive care unit. 
  • Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. 
  • Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. 
  • Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. 
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. 
  • Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. 
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. 
  • Phenotypic properties of transmitted founder HIV-1 
  • Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. 
  • Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies. 
  • Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O. 
  • Physical and mental health in African American mothers with HIV. 
  • Physicians' attitudes and practices regarding treatment of HIV-infected patients. 
  • Physiological and psychosocial factors that predict HIV-related fatigue. 
  • Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. 
  • Pneumocystis pneumonia in HIV-positive adults, Malawi. 
  • Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. 
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. 
  • Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. 
  • Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. 
  • Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. 
  • Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. 
  • Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. 
  • Positive choices: outcomes of a brief risk reduction intervention for newly HIV-diagnosed men who have sex with men. 
  • Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers. 
  • Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. 
  • Postbinding functions of CD4 in HIV infection. 
  • Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. 
  • Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers. 
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 
  • Postpartum depression and HIV infection among women in Malawi. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. 
  • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
  • Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. 
  • Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. 
  • Potentially traumatic experiences and sexual health among orphaned and separated adolescents in five low- and middle-income countries. 
  • Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. 
  • Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population. 
  • Predicting demographic group structures based on DNA sequence data. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Prediction uncertainty and optimal experimental design for learning dynamical systems. 
  • Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. 
  • Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. 
  • Predictors of condom use and human immunodeficiency virus test seeking among women living in inner-city public housing developments. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. 
  • Predictors of glycaemic control among HIV-positive veterans with diabetes. 
  • Predictors of high and low levels of HIV risk behavior among adults with chronic mental illness. 
  • Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. 
  • Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. 
  • Predictors of parent-adolescent communication in post-apartheid South Africa: a protective factor in adolescent sexual and reproductive health. 
  • Predictors of proteinuria and renal failure among women with HIV infection. 
  • Predictors of the severity of acute pancreatitis in patients with HIV infection or AIDS. 
  • Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. 
  • Preexposure prophylaxis for HIV infection among African women. 
  • Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. 
  • Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. 
  • Preoperative immune status determines anal condyloma recurrence after surgical excision. 
  • Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. 
  • Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. 
  • Prevalence and correlates of intimate partner violence among women attending HIV voluntary counseling and testing in northern Tanzania, 2005-2008. 
  • Prevalence and predictors of HIV-related stigma among institutional- and community-based caregivers of orphans and vulnerable children living in five less-wealthy countries. 
  • Prevalence and predictors of depressive symptoms among HIV-positive men who inject drugs in Vietnam. 
  • Prevalence and predictors of major depression in HIV-infected patients on antiretroviral therapy in Bamenda, a semi-urban center in Cameroon. 
  • Prevalence and predictors of proteinuria in HIV-infected and uninfected pregnant women in Cameroon. 
  • Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. 
  • Prevalence of HIV infection in a general psychiatric outpatient population. 
  • Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. 
  • Prevalence of HTLV-I-associated T-cell lymphoma. 
  • Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. 
  • Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States. 
  • Prevalence of childhood sexual abuse and physical trauma in an HIV-positive sample from the deep south. 
  • Prevalence of mycobacteremia among HIV-infected infants and children in northern Tanzania. 
  • Prevalence of psychological trauma and association with current health and functioning in a sample of HIV-infected and HIV-uninfected Tanzanian adults. 
  • Prevalence, characteristics, and outcomes of HIV-positive women diagnosed with invasive cancer of the cervix in Kenya. 
  • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. 
  • Prevention of vertical transmission of HIV in resource-limited countries. 
  • Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. 
  • Primary and Secondary HIV Prevention Among Persons with Severe Mental Illness: Recent Findings. 
  • Primary care for patients infected with human immunodeficiency virus: a randomized controlled trial. 
  • Primary care of HIV infection. 
  • Primary care of patients infected with human immunodeficiency virus. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Profiles of Resilience and Psychosocial Outcomes among Young Black Gay and Bisexual Men. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. 
  • Program design and evaluation strategies for the Special Projects of National Significance Outreach Initiative. 
  • Progress in HIV-1 vaccine development. 
  • Progress in HIV-1 vaccine development. 
  • Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis. 
  • Progress in the understanding of HIV infection: an overview. 
  • Progress in vaccine development against SIV and HIV. 
  • Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. 
  • Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. 
  • Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. 
  • Prophylaxis after sexual exposure to HIV. 
  • Proportion of US congregations that have people living with HIV. 
  • Prospects for vaccine protection against HIV-1 infection and AIDS. 
  • Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. 
  • Protease inhibitors and avascular necrosis: a systematic review and meta-analysis. 
  • Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques. 
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Providers' attitudes towards treating depression and self-reported depression treatment practices in HIV outpatient care. 
  • Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania. 
  • Psychiatric and psychosocial correlates of sexual risk behavior among adults with severe mental illness. 
  • Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential. 
  • Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV. 
  • Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. 
  • Psychological interventions to prevent HIV infection are urgently needed. New priorities for behavioral research in the second decade of AIDS. 
  • Psychological symptoms among persons 50 years of age and older living with HIV disease. 
  • Psychosocial and behavioral correlates of depression among HIV-infected pregnant women. 
  • Psychosocial predictors of life satisfaction among persons living with HIV infection and AIDS. 
  • Psychosocial predictors of sexual HIV transmission risk behavior among HIV-positive adults with a sexual abuse history in childhood. 
  • Psychosocial vulnerability and HIV-related sexual risk among men who have sex with men and women in the United States. 
  • Pulmonary disease in children with AIDS. 
  • Putting prevention in their pockets: developing mobile phone-based HIV interventions for black men who have sex with men. 
  • Q fever, spotted fever group, and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania. 
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. 
  • Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. 
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. 
  • Race, social support, and coping strategies among HIV-positive gay and bisexual men. 
  • Racial/ethnic differences in the rates and correlates of HIV risk behaviors among drug abusers. 
  • Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. Community HIV Prevention Research Collaborative. 
  • Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial. 
  • Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus. 
  • Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. 
  • Rapid self testing for HIV infection. 
  • Rapid telomere shortening in children. 
  • Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. 
  • Rational testing of the HIV-exposed infant. 
  • Rationing HIV medications: what do patients and the public think about allocation policies? 
  • Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy. 
  • Real-time updates of meta-analyses of HIV treatments supported by a biomedical ontology. 
  • Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. 
  • Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. 
  • Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. 
  • Recent advances. HIV infection--I. 
  • Recent mobile health interventions to support medication adherence among HIV-positive MSM. 
  • Reciprocity and retaining African-American women with HIV in research. 
  • Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. 
  • Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. 
  • Reconsideration of HIV as a contraindication to transplantation. 
  • Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 
  • Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer. 
  • Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention. 
  • Reductions in alcohol and cocaine use following a group coping intervention for HIV-positive adults with childhood sexual abuse histories. 
  • Reductions in traumatic stress following a coping intervention were mediated by decreases in avoidant coping for people living with HIV/AIDS and childhood sexual abuse. 
  • Reflections: A Case for Intersectional Approaches in HIV Research. 
  • Reframing and understanding the HIV epidemic in MSM: masculinity, racism, and homophobia. 
  • Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. 
  • Regulation of human immunodeficiency virus replication. 
  • Relation of lifetime trauma and depressive symptoms to mortality in HIV. 
  • Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 
  • Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care. 
  • Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. 
  • Relationship between trauma and high-risk behavior among HIV-positive men who do not have sex with men (MDSM). 
  • Relationship type, condom use and HIV/AIDS risks among men who have sex with men in six Chinese cities. 
  • Reliable genotypic tropism tests for the major HIV-1 subtypes. 
  • Religion and HIV in Tanzania: influence of religious beliefs on HIV stigma, disclosure, and treatment attitudes. 
  • Renal TGF-beta in HIV-associated kidney diseases. 
  • Renal epithelium is a previously unrecognized site of HIV-1 infection. 
  • Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. 
  • Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. 
  • Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. 
  • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. 
  • Reply to L. Dal Maso et al. 
  • Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. 
  • Research on HIV cure: Mapping the ethics landscape. 
  • Resilience, stress, and life quality in older adults living with HIV/AIDS. 
  • Resiliency among individuals with childhood sexual abuse and HIV: perspectives on addressing sexual trauma. 
  • Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. 
  • Respondent driven sampling is an effective method for engaging methamphetamine users in HIV prevention research in South Africa. 
  • Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. 
  • Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. 
  • Results of the NIMH collaborative HIV/sexually transmitted disease prevention trial of a community popular opinion leader intervention. 
  • Retinal arterioles narrow with increasing duration of anti-retroviral therapy in HIV infection: a novel estimator of vascular risk in HIV? 
  • Retinal vascular parameter variations in patients with human immunodeficiency virus. 
  • Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection. 
  • Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. 
  • Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. 
  • Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. 
  • Risk factors for cervical precancer detection among previously unscreened HIV-infected women in Western Kenya. 
  • Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. 
  • Risks, reactions, regulations, and reality. Health care workers with HIV infection. 
  • Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. 
  • Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. 
  • Role of HIV membrane in neutralization by two broadly neutralizing antibodies. 
  • Role of chemokine receptors in HIV-1 infection and pathogenesis. 
  • Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. 
  • Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. 
  • Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. 
  • Rural-urban differences in HIV viral loads and progression to AIDS among new HIV cases. 
  • SAMMA, a mandelic acid condensation polymer, inhibits dendritic cell-mediated HIV transmission. 
  • Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. 
  • Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. 
  • Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. 
  • Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. 
  • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. 
  • Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. 
  • Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. 
  • Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. 
  • Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. 
  • Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. 
  • Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. 
  • Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. 
  • Safety of the loop electrosurgical excision procedure performed by clinical officers in an HIV primary care setting. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • San Francisco's HIV infection rate doubles. 
  • Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. 
  • Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. 
  • Scientific and social issues of human immunodeficiency virus vaccine development. 
  • Screening surgeons for HIV infection: assessment of a potential public health program. 
  • Seasonal variation in the etiology of bloodstream infections in a febrile inpatient population in a developing country. 
  • Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. 
  • Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. 
  • Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. 
  • Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. 
  • Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. 
  • Self-Efficacy for Sexual Risk Reduction and Partner HIV Status as Correlates of Sexual Risk Behavior Among HIV-Positive Adolescent Girls and Women. 
  • Self-compassion and reactions to serious illness: the case of HIV. 
  • Self-disclosure of HIV status, disclosure counseling, and retention in HIV care in Cameroon. 
  • Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. 
  • Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. 
  • Sensitivity analysis on a chance node with more than two branches. 
  • Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 
  • Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system. 
  • Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. 
  • Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. 
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. 
  • Sexual Mixing in Shanghai: Are Heterosexual Contact Patterns Compatible With an HIV/AIDS Epidemic? 
  • Sexual abuse of human immunodeficiency virus-positive children. Outcomes for perpetrators and evaluation of other household children. 
  • Sexual behavior of HIV discordant couples after HIV counseling and testing. 
  • Sexual orientation differences in HIV testing motivation among college men. 
  • Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. 
  • Shooting at a moving target: natural history studies and the rapidly improving state of anti-HIV treatment. 
  • Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. 
  • Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques. 
  • Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. 
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. 
  • Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Simultaneous Detection of Major Drug Resistance Mutations of HIV-1 Subtype B Viruses from Dried Blood Spot Specimens by Multiplex Allele-Specific Assay. 
  • Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. 
  • Skin manifestations of HIV-1 infection in children. 
  • Slowing the spread of HIV: agenda for the 1990s. 
  • So much for keeping secrets: the importance of considering patients' perspectives on maintaining confidentiality. 
  • Social Network Clustering and the Spread of HIV/AIDS Among Persons Who Inject Drugs in 2 Cities in the Philippines. 
  • Sociodemographic and clinical characteristics of clients presenting for HIV voluntary counselling and testing in Moshi, Tanzania. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 
  • Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. 
  • Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Solid-organ transplantation in HIV-infected patients. 
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. 
  • Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. 
  • Specific activation strategies for amplification of low CTL signals. 
  • Spectrum of HIV antibodies in vaccine and disease. 
  • Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. 
  • Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. 
  • Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis. 
  • Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. 
  • Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Strategies of antiretroviral therapy in adults. 
  • Stressful and traumatic life events as disruptors to antiretroviral therapy adherence. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structural interventions in public health. 
  • Structure and immune recognition of trimeric pre-fusion HIV-1 Env. 
  • Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. 
  • Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. 
  • Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. 
  • Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity. 
  • Substance abuse and symptoms of mental illness among HIV-positive persons in the Southeast. 
  • Substance use and HIV infection awareness among HIV-infected female sex workers in Lilongwe, Malawi. 
  • Substance use, sexual risk, and violence: HIV prevention intervention with sex workers in Pretoria. 
  • Substitution model of sequence evolution for the human immunodeficiency virus type 1 subtype B gp120 gene over the C2-V5 region. 
  • Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. 
  • Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 
  • Suicidal Ideation is Associated with Limited Engagement in HIV Care. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. 
  • Syringe exchanges: a public health response to problem drug use. 
  • Systematic review of the performance of HIV viral load technologies on plasma samples. 
  • Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. 
  • Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. 
  • T-Cell receptor Vbeta repertoire CDR3 length diversity differs within CD45RA and CD45RO T-cell subsets in healthy and human immunodeficiency virus-infected children. 
  • T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. 
  • TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. 
  • TTP following ITP in an HIV-positive boy. 
  • Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. 
  • Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. 
  • Taste and smell complaints in HIV-infected patients. 
  • Teaching health professionals to teach. 
  • Telomere length is associated with sleep duration but not sleep quality in adults with human immunodeficiency virus. 
  • Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. 
  • Ten years later: a single hospital experience with malignancy in HIV/AIDS. 
  • Test site predicts HIV care linkage and antiretroviral therapy initiation: a prospective 3.5 year cohort study of HIV-positive testers in northern Tanzania. 
  • Testing for risk and protective trends in genetic analyses of HIV acquisition. 
  • Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. 
  • Text messaging for enhancement of testing and treatment for tuberculosis, human immunodeficiency virus, and syphilis: a survey of attitudes toward cellular phones and healthcare. 
  • Thanks for the memories. 
  • The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year. 
  • The Acceptability and Potential Utility of Cognitive Training to Improve Working Memory in Persons Living With HIV: A Preliminary Randomized Trial. 
  • The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. 
  • The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. 
  • The Challenge of Community Representation. 
  • The Cognitive Escape Scale: measuring HIV-related thought avoidance. 
  • The Cryptococcus neoformans transcriptome at the site of human meningitis. 
  • The Development of an HIV Training Program for Nurse Practitioners. 
  • The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. 
  • The Effects of RANTES Polymorphisms on Susceptibility to HIV-1 Infection and Disease Progression: Evidence from an Updated Meta-Analysis. 
  • The Feasibility and Acceptability of Using Technology-Based Daily Diaries with HIV-Infected Young Men Who have Sex with Men: A Comparison of Internet and Voice Modalities. 
  • The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi. 
  • The HIV cytopathic effect: potential target for therapy? 
  • The HIV epidemic and the primary care physician. 
  • The HIV-AIDS pandemic at 25--the global response. 
  • The HIV-positive traveler. 
  • The Immunology Quality Assessment Proficiency Testing Program for CD3⁺4⁺ and CD3⁺8⁺ lymphocyte subsets: a ten year review via longitudinal mixed effects modeling. 
  • The Impact of Couple HIV Testing and Counseling on Consistent Condom Use Among Pregnant Women and Their Male Partners: An Observational Study. 
  • The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. 
  • The President's Emergency Plan for AIDS Relief: from successes of the emergency response to challenges of sustainable action. 
  • The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care. 
  • The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. 
  • The antibody response in HIV-1 infection. 
  • The association of HIV counseling and testing with HIV risk behaviors in a random population-based survey in Kisumu, Kenya. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The clinical significance of change in trauma-related symptoms following a pilot group intervention for coping with HIV-AIDS and childhood sexual trauma. 
  • The design and evaluation of HIV-1 vaccines. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The dilemmas of childhood HIV infection. 
  • The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. 
  • The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. 
  • The effect of exposure to wood smoke on outcomes of childhood pneumonia in Botswana. 
  • The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. 
  • The effects on survival of early treatment of human immunodeficiency virus infection. 
  • The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. 
  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. 
  • The five-site health and risk study of blood-borne infections among persons with severe mental illness. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The future of digital games for HIV prevention and care. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The global health and diagnostic (flow) cytometry--breakthroughs in HIV and tuberculosis. 
  • The history and challenge of HIV prevention. 
  • The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. 
  • The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. 
  • The humoral response to HIV-1: new insights, renewed focus. 
  • The immune response during acute HIV-1 infection: clues for vaccine development. 
  • The immune response to HIV: implications for vaccine development. 
  • The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. 
  • The impact of ancillary services on primary care use and outcomes for HIV/AIDS patients with public insurance coverage. 
  • The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. 
  • The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. 
  • The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. 
  • The impact of shame on health-related quality of life among HIV-positive adults with a history of childhood sexual abuse. 
  • The importance of spirituality/religion and health-related quality of life among individuals with HIV/AIDS. 
  • The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services. 
  • The inference of stepwise changes in substitution rates using serial sequence samples. 
  • The influence of personality disorder indication, social support, and grief on alcohol and cocaine use among HIV-positive adults coping with AIDS-related bereavement. 
  • The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. 
  • The name game: lamivudine-lamotrigine dispensing error presenting as human immunodeficiency virus-associated fever of unknown origin. 
  • The natural history of hepatitis C viral infection. 
  • The pharmacoeconomics of HIV disease. 
  • The pharmacologic management of insomnia in patients with HIV. 
  • The process of HIV status disclosure to HIV-positive youth in Kinshasa, Democratic Republic of the Congo. 
  • The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. 
  • The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. 
  • The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? 
  • The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. 
  • The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack. 
  • The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based Clinical Trials Network. 
  • The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. 
  • The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. 
  • The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa. 
  • The social injustice of the HIV/AIDS epidemic. 
  • The structure of coping among older adults living with HIV/AIDS and depressive symptoms. 
  • The time has come to make cervical cancer prevention an essential part of comprehensive sexual and reproductive health services for HIV-positive women in low-income countries. 
  • The unrealized benefits of antiretroviral therapy. 
  • The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. 
  • The usefulness of an assessment of emotional involvement of HIV-positive mothers and their infants. 
  • The value of certification in HIV/AIDS nursing. 
  • Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. 
  • Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. 
  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. 
  • Topical microbicides: the time has come. 
  • Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. 
  • Total shoulder arthroplasty in patients with HIV infection: complications, comorbidities, and trends. 
  • Toward a metasynthesis of qualitative findings on motherhood in HIV-positive women. 
  • Toward an understanding of the correlates of protective immunity to HIV infection. 
  • Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays. 
  • Toward elimination of perinatal HIV transmission: New Jersey hospital barriers to rapid HIV testing in labor and delivery, 2005. 
  • Transcriptional network predicts viral set point during acute HIV-1 infection. 
  • Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity. 
  • Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. 
  • Translating tuberculosis research into practice: collaboration between academic researchers and public health departments in North Carolina. 
  • Transmissible agents and the surgeon. 
  • Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. 
  • Trauma history and depression predict incomplete adherence to antiretroviral therapies in a low income country. 
  • Trauma, stressful life events and depression predict HIV-related fatigue. 
  • Traumatic stress and the mediating role of alcohol use on HIV-related sexual risk behavior: results from a longitudinal cohort of South African women who attend alcohol-serving venues. 
  • Treating maladaptive grief and posttraumatic stress symptoms in orphaned children in Tanzania: group-based trauma-focused cognitive-behavioral therapy. 
  • Treating posttraumatic stress disorder in people with HIV. 
  • Treatment Failures and Excess Mortality Among HIV-Exposed, Uninfected Children With Pneumonia. 
  • Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. 
  • Treatment of children with HIV infection. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Treatment of hepatitis C in special populations. 
  • Treatment of hepatitis C in special populations. 
  • Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection. 
  • Treatment retention and care transitions during and after the scale-up of HIV care and treatment in Northern Tanzania. 
  • Trends in HIV testing and differences between planned and actual testing in the United States, 2000-2005. 
  • Trends in health care resource use for hepatitis C virus infection in the United States. 
  • Trends in primary central nervous system lymphoma incidence and survival in the U.S. 
  • Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. 
  • Trends of human immunodeficiency virus type-1 infection in female prostitutes and males diagnosed with a sexually transmitted disease in Djibouti, east Africa. 
  • Trichomonas vaginalis as a cause of urethritis in Malawian men. 
  • Triply-diagnosed patients in the HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study: patterns of home care use. 
  • Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review. 
  • Tuberculosis among health care workers in KwaZulu-Natal, South Africa: a retrospective cohort analysis. 
  • Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. 
  • Tuberculous pericarditis in Tanzanian patients with and without HIV infection. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. 
  • Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. 
  • Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. 
  • Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. 
  • University leadership for innovation in global health and HIV/AIDS diagnostics. 
  • Unprotected intercourse for extra money among commercial sex workers in Kinshasa, Democratic Republic of Congo. 
  • Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. 
  • Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. 
  • Use of a brief behavioral skills intervention to prevent HIV infection among chronic mentally ill adults. 
  • Use of a brief version of the self-compassion inventory with an international sample of people with HIV/AIDS. 
  • Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. 
  • Use of psychiatric and medical health care by veterans with severe mental illness. 
  • Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. 
  • User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. 
  • Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 
  • Using Cognitive Interviews to Enhance Measurement in Empirical Bioethics: Developing a Measure of the Preventive Misconception in Biomedical HIV Prevention Trials. 
  • Using an intersectional approach to study the impact of social determinants of health for African American mothers living with HIV. 
  • Using qualitative metasummary to synthesize qualitative and quantitative descriptive findings. 
  • Using syndemic theory to understand vulnerability to HIV infection among Black and Latino men in New York City. 
  • Using technology to assess and intervene with illicit drug-using persons at risk for HIV. 
  • Using technology to support HIV self-testing among MSM. 
  • Utility of a brief computerized battery to assess HIV-associated neurocognitive impairment in a resource-limited setting. 
  • Utility of rapid antibody tests to exclude HIV-1 infection among infants and children aged <18 months in a low-resource setting. 
  • Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. 
  • Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. 
  • Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse. 
  • Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. 
  • V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. 
  • VISION: a regional performance improvement initiative for HIV health care providers. 
  • Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. 
  • Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. 
  • Vaccine development for HIV infection. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. 
  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. 
  • Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. 
  • Vaginal drug distribution modeling. 
  • Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design. 
  • Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients. 
  • Validation, performance under field conditions, and cost-effectiveness of Capillus HIV-1/HIV-2 and determine HIV-1/2 rapid human immunodeficiency virus antibody assays using sequential and parallel testing algorithms in Tanzania. 
  • Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. 
  • Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa. 
  • Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. 
  • Values that Fathers Communicate to Sons about Sex, Sexuality, Relationships, and Marriage. 
  • Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. 
  • Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis. 
  • Veterans Living with HIV: A High-Risk Group for Cigarette Smoking. 
  • Violence against substance-abusing South African sex workers: intersection with culture and HIV risk. 
  • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. 
  • Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. 
  • Voices of Women Facing HIV-Related Stigma in the Deep South. 
  • Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. 
  • When "need plus supply" does not equal demand: challenges in uptake of depression treatment in HIV clinical care. 
  • When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. 
  • When children harbor HIV. 
  • Who tests, who doesn't, and why? Uptake of mobile HIV counseling and testing in the Kilimanjaro Region of Tanzania. 
  • Wide variation in the multiplicity of HIV-1 infection among injection drug users. 
  • Widow cleansing and inheritance among the Luo in Kenya: the need for additional women-centred HIV prevention options. 
  • Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design? 
  • Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. 
  • Working Toward 21(st) Century Interprofessional Workforce Training and Leadership in HIV Care. 
  • World Health Organization's stage 4 conditions among adults accessing outpatient HIV care: a retrospective cohort study in Kisumu, Kenya. 
  • Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. 
  • Young Men's Social Network Characteristics and Associations with Sexual Partnership Concurrency in Tanzania. 
  • Youth, Technology, and HIV: Recent Advances and Future Directions. 
  • Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. 
  • Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 
  • Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. 
  • chngpt: threshold regression model estimation and inference. 
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. 
  • Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection. 
  • λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. 
• 

  Keywords of People

  • Attarian, David Edward, Professor of Orthopaedic Surgery, Orthopaedics
  • Barfield, Raymond Carlton, Professor of Pediatrics, Duke Science & Society
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Broverman, Sherryl A., Associate Professor of the Practice of Biology, Biology
  • Cianciolo, George James, Associate Professor in Pathology, Pathology
  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Drucker, Robert Patrick, Professor of Pediatrics, School of Medicine
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Katz, David F., Nello L. Teer, Jr. Professor of Biomedical Engineering, in the Edmund T. Pratt, Jr. School of Engineering, Biomedical Engineering
  • Kelsoe, Garnett H., James B. Duke Professor of Immunology, Immunology
  • Klotman, Mary E, R.J. Reynolds Professor of Medicine, School of Medicine
  • Livingston, Elizabeth Gresham, Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Maternal Fetal Medicine
  • Merli, M. Giovanna, Professor in the Sanford School of Public Policy, Duke Global Health Institute
  • Murdoch, David Martin, Associate Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Relf, Michael Vernon, Associate Professor in the School of Nursing, with tenure, School of Nursing
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine, Immunology
  • Whetten, Kathryn, Professor in the Sanford School of Public Policy, School of Nursing
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine